Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders

Satish Srivastava, Umesh C S Yadav, Aramati B M Reddy, Ashish Saxena, Ravinder Tammali, Mohammad Shoeb, Naseem Ansari, Aruni Bhatnagar, Mark J. Petrash, Sanjay Srivastava, Kota Ramana

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Oxidative stress-induced inflammation is a major contributor to several disease conditions including sepsis, carcinogenesis and metastasis, diabetic complications, allergic asthma, uveitis and after cataract surgery posterior capsular opacification. Since reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors and subsequent expression of inflammatory cytokines, chemokines and growth factors are characteristics of inflammatory disorders, we envisioned that by blocking the molecular signals of ROS that activate redox-sensitive transcription factors, various inflammatory diseases could be ameliorated. We have indeed demonstrated that ROS-induced lipid peroxidation-derived lipid aldehydes such as 4-hydroxy-trans-2-nonenal (HNE) and their glutathione-conjugates (e.g. GS-HNE) are efficiently reduced by aldose reductase to corresponding alcohols which mediate the inflammatory signals. Our results showed that inhibition of aldose reductase (AKR1B1) significantly prevented the inflammatory signals induced by cytokines, growth factors, endotoxins, high glucose, allergens and auto-immune reactions in cellular as well as animal models. We have demonstrated that AKR1B1 inhibitor, fidarestat, significantly prevents tumor necrosis factor-alpha (TNF-α)-, growth factors-, lipopolysachharide (LPS)-, and environmental allergens-induced inflammatory signals that cause various inflammatory diseases. In animal models of inflammatory diseases such as diabetes, cardiovascular, uveitis, asthma, and cancer (colon, breast, prostate and lung) and metastasis, inhibition of AKR1B1 significantly ameliorated the disease. Our results from various cellular and animal models representing a number of inflammatory conditions suggest that ROS-induced inflammatory response could be reduced by inhibition of AKR1B1, thereby decreasing the progression of the disease and if the therapy is initiated early, the disease could be eliminated. Since fidarestat has already undergone phase III clinical trial for diabetic neuropathy and found to be safe, though clinically not very effective, our results indicate that it can be developed for the therapy of a number of inflammation-related diseases. Our results thus offer a novel therapeutic approach to treat a wide array of inflammatory diseases.

Original languageEnglish
Pages (from-to)330-338
Number of pages9
JournalChemico-Biological Interactions
Volume191
Issue number1-3
DOIs
StatePublished - May 30 2011

Fingerprint

Aldehyde Reductase
Oxidative stress
Oxidative Stress
Reactive Oxygen Species
Intercellular Signaling Peptides and Proteins
Uveitis
Animals
Allergens
Oxidation-Reduction
Transcription Factors
Asthma
Animal Models
Cytokines
Neoplasm Metastasis
Inflammation
Animal Disease Models
Phase III Clinical Trials
Diabetic Neuropathies
Antigen-antibody reactions
Diabetes Complications

Keywords

  • Aldose reductase
  • Asthma
  • Colon cancer
  • Inflammation
  • Oxidative stress
  • Uveitis

ASJC Scopus subject areas

  • Toxicology

Cite this

Srivastava, S., Yadav, U. C. S., Reddy, A. B. M., Saxena, A., Tammali, R., Shoeb, M., ... Ramana, K. (2011). Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chemico-Biological Interactions, 191(1-3), 330-338. https://doi.org/10.1016/j.cbi.2011.02.023

Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. / Srivastava, Satish; Yadav, Umesh C S; Reddy, Aramati B M; Saxena, Ashish; Tammali, Ravinder; Shoeb, Mohammad; Ansari, Naseem; Bhatnagar, Aruni; Petrash, Mark J.; Srivastava, Sanjay; Ramana, Kota.

In: Chemico-Biological Interactions, Vol. 191, No. 1-3, 30.05.2011, p. 330-338.

Research output: Contribution to journalArticle

Srivastava, S, Yadav, UCS, Reddy, ABM, Saxena, A, Tammali, R, Shoeb, M, Ansari, N, Bhatnagar, A, Petrash, MJ, Srivastava, S & Ramana, K 2011, 'Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders', Chemico-Biological Interactions, vol. 191, no. 1-3, pp. 330-338. https://doi.org/10.1016/j.cbi.2011.02.023
Srivastava S, Yadav UCS, Reddy ABM, Saxena A, Tammali R, Shoeb M et al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chemico-Biological Interactions. 2011 May 30;191(1-3):330-338. https://doi.org/10.1016/j.cbi.2011.02.023
Srivastava, Satish ; Yadav, Umesh C S ; Reddy, Aramati B M ; Saxena, Ashish ; Tammali, Ravinder ; Shoeb, Mohammad ; Ansari, Naseem ; Bhatnagar, Aruni ; Petrash, Mark J. ; Srivastava, Sanjay ; Ramana, Kota. / Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. In: Chemico-Biological Interactions. 2011 ; Vol. 191, No. 1-3. pp. 330-338.
@article{8c50e435439941fca1dfdd9c82c78270,
title = "Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders",
abstract = "Oxidative stress-induced inflammation is a major contributor to several disease conditions including sepsis, carcinogenesis and metastasis, diabetic complications, allergic asthma, uveitis and after cataract surgery posterior capsular opacification. Since reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors and subsequent expression of inflammatory cytokines, chemokines and growth factors are characteristics of inflammatory disorders, we envisioned that by blocking the molecular signals of ROS that activate redox-sensitive transcription factors, various inflammatory diseases could be ameliorated. We have indeed demonstrated that ROS-induced lipid peroxidation-derived lipid aldehydes such as 4-hydroxy-trans-2-nonenal (HNE) and their glutathione-conjugates (e.g. GS-HNE) are efficiently reduced by aldose reductase to corresponding alcohols which mediate the inflammatory signals. Our results showed that inhibition of aldose reductase (AKR1B1) significantly prevented the inflammatory signals induced by cytokines, growth factors, endotoxins, high glucose, allergens and auto-immune reactions in cellular as well as animal models. We have demonstrated that AKR1B1 inhibitor, fidarestat, significantly prevents tumor necrosis factor-alpha (TNF-α)-, growth factors-, lipopolysachharide (LPS)-, and environmental allergens-induced inflammatory signals that cause various inflammatory diseases. In animal models of inflammatory diseases such as diabetes, cardiovascular, uveitis, asthma, and cancer (colon, breast, prostate and lung) and metastasis, inhibition of AKR1B1 significantly ameliorated the disease. Our results from various cellular and animal models representing a number of inflammatory conditions suggest that ROS-induced inflammatory response could be reduced by inhibition of AKR1B1, thereby decreasing the progression of the disease and if the therapy is initiated early, the disease could be eliminated. Since fidarestat has already undergone phase III clinical trial for diabetic neuropathy and found to be safe, though clinically not very effective, our results indicate that it can be developed for the therapy of a number of inflammation-related diseases. Our results thus offer a novel therapeutic approach to treat a wide array of inflammatory diseases.",
keywords = "Aldose reductase, Asthma, Colon cancer, Inflammation, Oxidative stress, Uveitis",
author = "Satish Srivastava and Yadav, {Umesh C S} and Reddy, {Aramati B M} and Ashish Saxena and Ravinder Tammali and Mohammad Shoeb and Naseem Ansari and Aruni Bhatnagar and Petrash, {Mark J.} and Sanjay Srivastava and Kota Ramana",
year = "2011",
month = "5",
day = "30",
doi = "10.1016/j.cbi.2011.02.023",
language = "English",
volume = "191",
pages = "330--338",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders

AU - Srivastava, Satish

AU - Yadav, Umesh C S

AU - Reddy, Aramati B M

AU - Saxena, Ashish

AU - Tammali, Ravinder

AU - Shoeb, Mohammad

AU - Ansari, Naseem

AU - Bhatnagar, Aruni

AU - Petrash, Mark J.

AU - Srivastava, Sanjay

AU - Ramana, Kota

PY - 2011/5/30

Y1 - 2011/5/30

N2 - Oxidative stress-induced inflammation is a major contributor to several disease conditions including sepsis, carcinogenesis and metastasis, diabetic complications, allergic asthma, uveitis and after cataract surgery posterior capsular opacification. Since reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors and subsequent expression of inflammatory cytokines, chemokines and growth factors are characteristics of inflammatory disorders, we envisioned that by blocking the molecular signals of ROS that activate redox-sensitive transcription factors, various inflammatory diseases could be ameliorated. We have indeed demonstrated that ROS-induced lipid peroxidation-derived lipid aldehydes such as 4-hydroxy-trans-2-nonenal (HNE) and their glutathione-conjugates (e.g. GS-HNE) are efficiently reduced by aldose reductase to corresponding alcohols which mediate the inflammatory signals. Our results showed that inhibition of aldose reductase (AKR1B1) significantly prevented the inflammatory signals induced by cytokines, growth factors, endotoxins, high glucose, allergens and auto-immune reactions in cellular as well as animal models. We have demonstrated that AKR1B1 inhibitor, fidarestat, significantly prevents tumor necrosis factor-alpha (TNF-α)-, growth factors-, lipopolysachharide (LPS)-, and environmental allergens-induced inflammatory signals that cause various inflammatory diseases. In animal models of inflammatory diseases such as diabetes, cardiovascular, uveitis, asthma, and cancer (colon, breast, prostate and lung) and metastasis, inhibition of AKR1B1 significantly ameliorated the disease. Our results from various cellular and animal models representing a number of inflammatory conditions suggest that ROS-induced inflammatory response could be reduced by inhibition of AKR1B1, thereby decreasing the progression of the disease and if the therapy is initiated early, the disease could be eliminated. Since fidarestat has already undergone phase III clinical trial for diabetic neuropathy and found to be safe, though clinically not very effective, our results indicate that it can be developed for the therapy of a number of inflammation-related diseases. Our results thus offer a novel therapeutic approach to treat a wide array of inflammatory diseases.

AB - Oxidative stress-induced inflammation is a major contributor to several disease conditions including sepsis, carcinogenesis and metastasis, diabetic complications, allergic asthma, uveitis and after cataract surgery posterior capsular opacification. Since reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors and subsequent expression of inflammatory cytokines, chemokines and growth factors are characteristics of inflammatory disorders, we envisioned that by blocking the molecular signals of ROS that activate redox-sensitive transcription factors, various inflammatory diseases could be ameliorated. We have indeed demonstrated that ROS-induced lipid peroxidation-derived lipid aldehydes such as 4-hydroxy-trans-2-nonenal (HNE) and their glutathione-conjugates (e.g. GS-HNE) are efficiently reduced by aldose reductase to corresponding alcohols which mediate the inflammatory signals. Our results showed that inhibition of aldose reductase (AKR1B1) significantly prevented the inflammatory signals induced by cytokines, growth factors, endotoxins, high glucose, allergens and auto-immune reactions in cellular as well as animal models. We have demonstrated that AKR1B1 inhibitor, fidarestat, significantly prevents tumor necrosis factor-alpha (TNF-α)-, growth factors-, lipopolysachharide (LPS)-, and environmental allergens-induced inflammatory signals that cause various inflammatory diseases. In animal models of inflammatory diseases such as diabetes, cardiovascular, uveitis, asthma, and cancer (colon, breast, prostate and lung) and metastasis, inhibition of AKR1B1 significantly ameliorated the disease. Our results from various cellular and animal models representing a number of inflammatory conditions suggest that ROS-induced inflammatory response could be reduced by inhibition of AKR1B1, thereby decreasing the progression of the disease and if the therapy is initiated early, the disease could be eliminated. Since fidarestat has already undergone phase III clinical trial for diabetic neuropathy and found to be safe, though clinically not very effective, our results indicate that it can be developed for the therapy of a number of inflammation-related diseases. Our results thus offer a novel therapeutic approach to treat a wide array of inflammatory diseases.

KW - Aldose reductase

KW - Asthma

KW - Colon cancer

KW - Inflammation

KW - Oxidative stress

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=79957549510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957549510&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2011.02.023

DO - 10.1016/j.cbi.2011.02.023

M3 - Article

VL - 191

SP - 330

EP - 338

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1-3

ER -